VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EMN 2021 | COVID-19 outcomes for myeloma patients receiving lenalidomide maintenance

Meral Beksac, MD, Ankara University, Ankara, Turkey, gives an overview of study investigating the outcomes of patients with COVID-19 infections who are receiving lenalidomide maintenance therapy, as presented at EMN 2021. Data was analyzed from 48 patients with multiple myeloma who were also diagnosed with a COVID-19 infection. The study found that patients receiving lenalidomide maintenance therapy had a COVID-19 infection fatality rate of 30.4%, compared to a rate of 48% for patients who were not receiving lenalidomide maintenance therapy. This interview took place during the 2021 European Myeloma Network (EMN) congress.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter